DURHAM, N.C.--(BUSINESS WIRE)--Phase Bioscience, Inc. (PhaseBio) announced today that it has concluded a Licensing Agreement with Duke University for the acquisition of certain intellectual property associated with the delivery of therapeutic agents based on ELP technology. Under the terms of the agreement PhaseBio will have worldwide rights to use the technology to develop its own portfolio of products as well as enter into third party arrangements for co-development and licensing.
